Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016', provides in depth analysis on Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted pipeline therapeutics. 

The report provides comprehensive information on the Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30)
- The report reviews Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD (+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Overview 10
Therapeutics Development 11
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Stage of Development 11
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Therapy Area 12
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Indication 13
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Companies 17
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Universities/Institutes 23
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Therapeutics Assessment 25
Assessment by Monotherapy/Combination Products 25
Assessment by Mechanism of Action 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development 31
AbbVie Inc. 31
American Gene Technologies International Inc. 32
AstraZeneca Plc 33
BeiGene, Ltd. 34
Clovis Oncology, Inc. 35
Eisai Co., Ltd. 36
Hager Biosciences, LLC 37
IMPACT Therapeutics, Inc. 38
Jeil Pharmaceutical Co., Ltd. 39
Jiangsu Hengrui Medicine Co., Ltd. 40
Mitsubishi Tanabe Pharma Corporation 41
Nerviano Medical Sciences S.r.l. 42
Takeda Pharmaceutical Company Limited 43
Tesaro, Inc. 44
Teva Pharmaceutical Industries Ltd. 45
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Drug Profiles 46
ABT-767 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AGPD - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AZ-0108 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
BGB-290 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CK-102 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
E-7449 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
fluzoparib - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
IMP-04297 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
JPI-289 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
MP-124 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
niraparib - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
NMSP-118 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
NMSP-648 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
NMSP-914 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
olaparib - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
R-503 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
rucaparib phosphate - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Small Molecule to Inhibit PARP-1 for Undisclosed Indication - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecules to Inhibit PARP-1 for Colon Cancer - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
veliparib - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
XZ-120312 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
YHP-743 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Dormant Projects 93
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Discontinued Products 99
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Featured News & Press Releases 100
Jun 06, 2016: Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting 100
Jun 05, 2016: LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer 103
Jun 04, 2016: TESARO Provides Update on niraparib at ASCO Investor Briefing 105
Jun 04, 2016: Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation 105
May 19, 2016: Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting 106
May 18, 2016: TESARO Announces Three Abstracts on Niraparib to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting 107
May 18, 2016: AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer 108
May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 2016 109
Apr 27, 2016: Lynparzatm (Olaparib) Now Available To NHS Patients In England And Wales With BRCA-Mutated Ovarian Cancer 109
Apr 18, 2016: AstraZeneca Presents New Data On PARP Inhibitor Lynparza (olaparib) at the AACR 2016 Annual Meeting 110
Apr 14, 2016: Myriad Genetics announces presentation on niraparib study at the 2016 American Association for Cancer Research Annual Meeting 111
Jan 28, 2016: Lynparza (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer 111
Jan 27, 2016: NICE recommends olaparib for ovarian cancer 112
Jan 25, 2016: Clovis Oncology Names Dale Hooks as Chief Commercial Officer, Provides Update On Rucaparib 112
Dec 11, 2015: NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Development by Companies, H1 2016 (Contd..2) 20
Products under Development by Companies, H1 2016 (Contd..3) 21
Products under Development by Companies, H1 2016 (Contd..4) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Products under Investigation by Universities/Institutes, H1 2016 24
Assessment by Monotherapy/Combination Products, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Pipeline by AbbVie Inc., H1 2016 31
Pipeline by American Gene Technologies International Inc., H1 2016 32
Pipeline by AstraZeneca Plc, H1 2016 33
Pipeline by BeiGene, Ltd., H1 2016 34
Pipeline by Clovis Oncology, Inc., H1 2016 35
Pipeline by Eisai Co., Ltd., H1 2016 36
Pipeline by Hager Biosciences, LLC, H1 2016 37
Pipeline by IMPACT Therapeutics, Inc., H1 2016 38
Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 39
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 40
Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 41
Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 42
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 43
Pipeline by Tesaro, Inc., H1 2016 44
Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 45
Dormant Projects, H1 2016 93
Dormant Projects (Contd..1), H1 2016 94
Dormant Projects (Contd..2), H1 2016 95
Dormant Projects (Contd..3), H1 2016 96
Dormant Projects (Contd..4), H1 2016 97
Dormant Projects (Contd..5), H1 2016 98
Discontinued Products, H1 2016 99